{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:35:14Z","timestamp":1793450114614,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101057454"],"award-info":[{"award-number":["101057454"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbi.2026.106874","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:38:14Z","timestamp":1781800694000},"page":"106874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Inflammatory protein markers and treatment outcomes across mood and psychotic disorders: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6187-0187","authenticated-orcid":false,"given":"Chiara","family":"Possidente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Biancalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard T.","family":"Baune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2026.106874_b0005","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2012.03.033","article-title":"Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study","volume":"141","author":"Abbasi","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2026.106874_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.psychres.2019.07.005","article-title":"Heterogeneity in psychiatric diagnostic classification","volume":"279","author":"Allsopp","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2026.106874_b0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2018.07.077","article-title":"Characterizing the course of suicidal ideation response to ketamine","volume":"241","author":"Ballard","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2026.106874_b0020","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgab017","article-title":"Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with first episode psychosis: the OPTiMiSE Cohort Study","volume":"2","author":"Barbosa","year":"2021","journal-title":"Schizophr Bull Open"},{"key":"10.1016\/j.bbi.2026.106874_b0025","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00406-024-01944-3","article-title":"A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe","volume":"275","author":"Baune","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2026.106874_b0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.euroneuro.2020.11.009","article-title":"Higher baseline interleukin-1\u03b2 and TNF-\u03b1 hamper antidepressant response in major depressive disorder","volume":"42","author":"Benedetti","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2026.106874_b0035","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1192\/j.eurpsy.2025.10102","article-title":"Boulevard of broken rhythms: a systematic review and meta-analysis on the relationship between sleep disturbances and suicidal behavior in bipolar disorder","volume":"68","author":"Bort","year":"2025","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41398-019-0521-7","article-title":"Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies","volume":"9","author":"Carboni","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41398-021-01581-7","article-title":"Predictive values of tumor necrosis factor-\u03b1 for depression treatment outcomes: effect modification by hazardous alcohol consumption","volume":"11","author":"Choi","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0050","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2019.11.020","article-title":"Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders","volume":"179","author":"Cross-Disorder Group of the Psychiatric Genomics Consortium","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bbi.2026.106874_b0055","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1017\/S1092852916000572","article-title":"Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in \u201creal-world,\u201d everyday clinical practice","volume":"22","author":"De Berardis","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.bbi.2026.106874_b0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neulet.2018.05.030","article-title":"Escitalopram augmentation improves negative symptoms of treatment resistant schizophrenia patients \u2013 a randomized controlled trial","volume":"681","author":"Ding","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbi.2026.106874_b0065","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1021\/acs.jproteome.5b00803","article-title":"Impact of serum and plasma matrices on the titration of human inflammatory biomarkers using analytically validated SRM assays","volume":"15","author":"Dupin","year":"2016","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbi.2026.106874_b0070","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.bbi.2026.106874_b0075","doi-asserted-by":"crossref","DOI":"10.5080\/u26698","article-title":"Investigation of the relationship between inflammation and oxidative stress markers and treatment response in first attack major depression patients: A Follow-up Study","author":"Emekdar","year":"2023","journal-title":"Turk. J. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111183","article-title":"Shared polygenic susceptibility to treatment response in severe affective and psychotic disorders: evidence from GWAS data sets","volume":"136","author":"Facal","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0085","first-page":"317","article-title":"Changes of serum TNF-\u03b1, IL-6 and IL-18 levels in depressive disorder patients before and after treatment","volume":"33","author":"Fan","year":"2022","journal-title":"Sichuan Ment Health"},{"key":"10.1016\/j.bbi.2026.106874_b0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.euroneuro.2022.06.001","article-title":"Charting the proteome landscape in major psychiatric disorders: from biomarkers to biological pathways towards drug discovery","volume":"61","author":"Fernandes","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2026.106874_b0095","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S2215-0366(16)30370-4","article-title":"C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis","volume":"3","author":"Fernandes","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF02900219","article-title":"Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission","volume":"247","author":"Frommberger","year":"1997","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2026.106874_b0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.64719\/pb.4425","article-title":"Inflammatory biomarker and response to antidepressant in major depressive disorder: a systematic review and meta-analysis","volume":"52","author":"Gasparini","year":"2022","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.bbi.2026.106874_b0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"Gbd","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0120","article-title":"Making sense of blood-based proteomics and metabolomics in psychiatric research","volume":"19","author":"Guest","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2026.106874_b0125","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0269881109102770","article-title":"Elevated C-reactive protein in depression: a predictor of good long-term outcome with antidepressants and poor outcome with psychotherapy","volume":"24","author":"Harley","year":"2010","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.bbi.2026.106874_b0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41537-024-00483-z","article-title":"Elevated serum kynurenic acid in individuals with first-episode psychosis and insufficient response to antipsychotics","volume":"10","author":"Hatzimanolis","year":"2024","journal-title":"Schizophrenia"},{"key":"10.1016\/j.bbi.2026.106874_b0135","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3389\/fpsyt.2019.00378","article-title":"Baseline serum levels of Beclin-1, but not inflammatory factors, may predict antidepressant treatment response in chinese han patients with MDD: a preliminary study","volume":"10","author":"He","year":"2019","journal-title":"Front. Psych."},{"key":"10.1016\/j.bbi.2026.106874_b0140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: state of the art and new directions","volume":"27","author":"Howes","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0145","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1017\/S109285292300233X","article-title":"Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report","volume":"28","author":"Husain","year":"2023","journal-title":"CNS Spectr."},{"key":"10.1016\/j.bbi.2026.106874_b0150","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1021\/acs.jproteome.9b00503","article-title":"Mass spectrometry-based plasma proteomics: considerations from sample collection to achieving translational data","volume":"18","author":"Ignjatovic","year":"2019","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbi.2026.106874_b0155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psyneuen.2017.01.023","article-title":"Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial","volume":"78","author":"Jha","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bbi.2026.106874_b0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000484665","article-title":"Both serum brain-derived neurotrophic factor and Interleukin-6 levels are not associated with therapeutic response to lamotrigine augmentation therapy in treatment-resistant depressive disorder","volume":"75","author":"Kagawa","year":"2017","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.bbi.2026.106874_b0170","doi-asserted-by":"crossref","unstructured":"Kagaya A, Kugaya A, Takebayashi M, Fukue-Saeki M, Saeki T, Yamawaki S, et al. Plasma Concentrations of Interleukin-1\u00df, Interleukin-6, Soluble Interleukin-2 Receptor and Tumor Necrosis Factor \u00b7 of Depressed Patients in Japan 2001.","DOI":"10.1159\/000054867"},{"key":"10.1016\/j.bbi.2026.106874_b0175","doi-asserted-by":"crossref","first-page":"182","DOI":"10.9758\/cpn.23.1071","article-title":"Use of serum biomarkers to aid antidepressant selection in depressive patients","volume":"22","author":"Kang","year":"2024","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.bbi.2026.106874_b0180","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jad.2022.08.047","article-title":"Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: an open label study","volume":"318","author":"Kang","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2026.106874_b0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/00207450108986549","article-title":"Effect of Risperidone on Serum Cytokines","volume":"111","author":"Kim","year":"2001","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.bbi.2026.106874_b0190","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41537-023-00398-1","article-title":"Inflammatory markers of symptomatic remission at 6 months in patients with first-episode schizophrenia","volume":"9","author":"Kim","year":"2023","journal-title":"Schizophrenia"},{"key":"10.1016\/j.bbi.2026.106874_b0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbi.2022.05.012","article-title":"Prospective associations of multimodal serum biomarkers with 12-week and 12-month remission in patients with depressive disorders receiving stepwise psychopharmacotherapy","volume":"104","author":"Kim","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2026.106874_b0200","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41398-021-01268-z","article-title":"Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers","volume":"11","author":"Kruse","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpsychires.2023.11.005","article-title":"Discovery and validation of protein biomarkers for monitoring the effectiveness of drug treatment for major depressive disorder","volume":"169","author":"Lee","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbi.2026.106874_b0210","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/0004867417720517","article-title":"ALDH2 modulated changes in cytokine levels and cognitive function in bipolar disorder: a 12-week follow-up study","volume":"52","author":"Lee","year":"2018","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0215","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00406-021-01359-4","article-title":"Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia","volume":"272","author":"Li","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.bbi.2026.106874_b0220","doi-asserted-by":"crossref","first-page":"e199735","DOI":"10.1001\/jamanetworkopen.2019.9735","article-title":"Use of Prediction Intervals in Network Meta-analysis","volume":"2","author":"Lin","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bbi.2026.106874_b0225","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41380-019-0474-5","article-title":"Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0230","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.comppsych.2019.01.003","article-title":"Changes in serum TNF-\u03b1, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge","volume":"90","author":"Luo","year":"2019","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0235","article-title":"Relationship between Curative effect and Serum Inflammatory Factors Level in Male patients with First-Episode Schizophrenia Treated with Olanzapine","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Psych."},{"key":"10.1016\/j.bbi.2026.106874_b0240","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hup.2525","article-title":"Evaluation of interleukin\u20106 and serotonin as biomarkers to predict response to fluoxetine","volume":"31","author":"Manoharan","year":"2016","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.bbi.2026.106874_b0245","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jad.2018.04.115","article-title":"Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression","volume":"237","author":"Mao","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2026.106874_b0250","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2022.12.028","article-title":"Longitudinal study of inflammation and relapse in schizophrenia","volume":"252","author":"Miller","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2026.106874_b0255","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pnpbp.2013.09.016","article-title":"BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine","volume":"48","author":"Ninan","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0260","article-title":"Bipolar disorders: an update on critical aspects","volume":"48","author":"Oliva","year":"2025","journal-title":"Lancet Reg Health - Eur"},{"key":"10.1016\/j.bbi.2026.106874_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13091382","article-title":"Immunological Biomarkers as Predictors of Treatment Response in Psychotic Disorders","volume":"13","author":"Orbe","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.bbi.2026.106874_b0270","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.intimp.2005.10.004","article-title":"Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines","volume":"6","author":"Pae","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbi.2026.106874_b0275","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpsychires.2016.09.025","article-title":"Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression","volume":"84","author":"Park","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbi.2026.106874_b0280","article-title":"Immuno-metabolic depression: from concept to implementation","volume":"48","author":"Penninx","year":"2025","journal-title":"Lancet Reg Health - Eur"},{"key":"10.1016\/j.bbi.2026.106874_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2024.104059","article-title":"Biomarkers of treatment-resistant schizophrenia: a systematic review","volume":"3","author":"Pisanu","year":"2024","journal-title":"Neurosci. Appl."},{"key":"10.1016\/j.bbi.2026.106874_b0290","unstructured":"R Core Team. R: A language and environment for statistical computing 2021."},{"key":"10.1016\/j.bbi.2026.106874_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111056","article-title":"Pharmacotherapeutic value of inflammatory and neurotrophic biomarkers in bipolar disorder: a systematic review","volume":"134","author":"Ruiz-Sastre","year":"2024","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbi.2024.09.003","article-title":"Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo","volume":"123","author":"Sampson","year":"2025","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2026.106874_b0305","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/YIC.0000000000000550","article-title":"Sex-controlled differences in sertraline and citalopram efficacies in major depressive disorder: a randomized, double-blind trial","volume":"40","author":"Shamabadi","year":"2025","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbi.2026.106874_b0310","first-page":"34","article-title":"Possibilities of using laboratory biomarkers for the objective diagnosis of depressive disorders","volume":"13","author":"Shamrey","year":"2021","journal-title":"He\u0432po\u043bo\u0433\u0438\u044f He\u0439po\u043fc\u0438x\u0438a\u0442p\u0438\u044f \u041fc\u0438xoco\u043ca\u0442\u0438\u043aa"},{"key":"10.1016\/j.bbi.2026.106874_b0315","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41398-024-02998-6","article-title":"Pharmacogenomic scores in psychiatry: systematic review of current evidence","volume":"14","author":"Sharew","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0320","series-title":"C-Reactive Protein: Clinical Relevance and Interpretation","author":"Singh","year":"2025"},{"key":"10.1016\/j.bbi.2026.106874_b0325","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12974-022-02429-7","article-title":"Changes in leukocytes and CRP in different stages of major depression","volume":"19","author":"Singh","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bbi.2026.106874_b0330","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopsych.2008.10.018","article-title":"The Interaction of Nuclear Factor-Kappa B and Cytokines is Associated with Schizophrenia","volume":"65","author":"Song","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0335","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.bbi.2026.106874_b0340","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bbi.2026.106874_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.bbi.2026.106874_b0350","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/npp.2014.9","article-title":"Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users","volume":"39","author":"Vogelzangs","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2026.106874_b0355","article-title":"Adjunctive minocycline for major depressive disorder: a sub-study exploring peripheral immune-inflammatory markers and associated treatment response","volume":"27","author":"Walker","year":"2023","journal-title":"Brain Behav Immun - Health"},{"key":"10.1016\/j.bbi.2026.106874_b0360","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jad.2019.03.008","article-title":"Potential serum biomarkers for the prediction of the efficacy of escitalopram for treating depression","volume":"250","author":"Xu","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2026.106874_b0365","article-title":"Immune dynamics throughout life in relation to sex hormones and perspectives gained from gender-affirming hormone therapy","volume":"15","author":"Yalcinkaya","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbi.2026.106874_b0370","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.biopsych.2014.06.021","article-title":"Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression","volume":"77","author":"Yang","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0375","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.pnpbp.2009.03.020","article-title":"Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression","volume":"33","author":"Yoshimura","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0380","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41398-020-00933-z","article-title":"Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder","volume":"10","author":"Zhan","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0385","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jad.2019.03.001","article-title":"Baseline serum C-reactive protein levels may predict antidepressant treatment responses in patients with major depressive disorder","volume":"250","author":"Zhang","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2026.106874_b0390","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pnpbp.2018.04.004","article-title":"Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels","volume":"85","author":"Zhang","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2026.106874_b0395","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jad.2022.02.069","article-title":"The association of C-reactive protein with responses to escitalopram antidepressant treatment in patients with major depressive disorder","volume":"306","author":"Zhou","year":"2022","journal-title":"J. Affect. Disord."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159126006227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159126006227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:27:10Z","timestamp":1793449630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159126006227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":77,"alternative-id":["S0889159126006227"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2026.106874","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory protein markers and treatment outcomes across mood and psychotic disorders: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2026.106874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106874"}}